Miraflores, Peru Clinical Trials

A listing of Miraflores, Peru clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 122 clinical trials
None
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

breast cancer
formalin-fixed paraffin-embedded
triple-negative breast cancer
measurable disease
cancer
Research Site
 (1.0 away) Contact site
  • 1387 views
  • 14 Oct, 2021
  • +309 other locations
None
Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

pirfenidone
nintedanib
pamrevlumab
idiopathic pulmonary fibrosis
diffusion capacity of the lung for carbon monoxide
Centro de Investigacion Ricardo Palma
 (0.8 away) Contact site
  • 349 views
  • 14 Oct, 2021
  • +227 other locations
None
Efficacy Safety and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

This study will evaluate the efficacy, safety, and pharmacokinetics (PK) of sugammadex (MK-8616) for reversal of both moderate and deep neuromuscular blockade (NMB) in pediatric participants aged birth to <2 years. The primary hypothesis of this study is that sugammadex is superior to neostigmine in reversing moderate NMB as measured …

atropine
neostigmine
glycopyrrolate
rocuronium
reversal of neuromuscular blockade
Instituto Nacional Cardiovascular Incor ( Site 3928)
 (2.5 away) Contact site
  • 4 views
  • 13 Oct, 2021
  • +37 other locations
None
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

mk-3475
measurable disease
cancer of the ovary
cancer
advanced cancer
Oncosalud ( Site 3200)
 (1.5 away) Contact site
  • 19 views
  • 15 Oct, 2021
  • +150 other locations
None
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due …

pemetrexed
kinase inhibitor
non-squamous non-small cell lung cancer
stage iv non-small cell lung cancer
osimertinib
Research Site
 (1.0 away) Contact site
  • 817 views
  • 29 Sep, 2021
  • +173 other locations
None
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

infarct
stemi
acute coronary syndrome
diabetes
myocardial infarction
6040017 - Clinica El Golf
 (1.0 away) Contact site
  • 1132 views
  • 13 Oct, 2021
  • +3432 other locations
None
A Phase 3 Efficacy Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

A study of zolbetuximab (IMAB362) plus mFOLFOX6 versus placebo plus mFOLFOX6 in subjects with Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical study for adult patients who have any of: advanced unresectable gastric …

Site PE51004
 (1.0 away) Contact site
  • 487 views
  • 15 Oct, 2021
  • +239 other locations
None
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer

epidermal growth factor
EGFR
epidermal growth factor receptor
cancer chemotherapy
lung carcinoma
Research Site
 (1.5 away) Contact site
  • 207 views
  • 03 Oct, 2021
  • +154 other locations
None
A Study to Determine the Efficacy Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) Metronidazole (MTZ) Versus Meropenem (MER) Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

A Phase 3 comparative study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI) Metronidazole (MTZ) versus Meropenem (MER) Colistin (COL) for the treatment of serious infections due to Gram negative bacteria.

ATM
antibiotic therapy
metronidazole
antibiotics
meropenem
Clinica Internacional - Unidad de Investigacion de la Clinica Internacional
 (4.3 away) Contact site
  • 193 views
  • 10 Oct, 2021
  • +189 other locations
None
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

The primary purpose of the study is to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II -IIIA and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).

lung carcinoma
systemic therapy
alopecia
Novartis Investigative Site
 (1.1 away) Contact site
  • 645 views
  • 21 Sep, 2021
  • +416 other locations